Zheng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zheng Wang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Chenhao Zhou
Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China
29 shared publications - Dongmei Gao
Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
29 shared publications - Fu Wang
Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
29 shared publications - Jia-Lei Sun
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P. R. China
29 shared publications - Jialei Weng
Department of Surgical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
29 shared publications - Min Xu
Shanghai Tenth People’s Hospital 1 Department of Thoracic Surgery Tongji University School of Medicine, Shanghai, P.R. China
29 shared publications
Latest Publications
- 11 September 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (10) , 1533-1554
MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy
Limited efficacy of neoadjuvant chemotherapy (NAC) in pancreatic ductal adenocarcinoma (PDAC) underscores the need for novel combination strategies and a deeper understanding of metabolic determinants of chemoresistance. Here we identify methylmalonate semialdehyde dehydrogenase (MMSDH), a valine catabolism enzyme, as a driver of gemcitabine (GC) resistance. Hypoxia induces GCN5-mediated lactylation of MMSDH at K113. Lactylated MMSDH interacts with acyl-CoA synthetase long-chain family member 4 (ACSL4), generating propionyl-CoA to facilitate KAT8-mediated ACSL4 K606 propionylation. This modification enhances ACSL4–HSC70 binding, promoting its degradation through chaperone-mediated autophagy. Critically, this MMSDH-mediated ACSL4 propionylation correlates with low ACSL4 levels and poor NAC response in recipients. Combining dietary valine restriction with GC synergistically induces ferroptosis and suppresses tumor growth. Blocking MMSDH-K113la disrupts this axis, potentiating GC-induced ferroptosis and inhibiting tumor progression. These findings reveal a previously unknown mechanism of ferroptosis evasion through valine metabolism and ACSL4 regulation, nominating the GCN5–MMSDH–ACSL4 axis as a therapeutic target to enhance PDAC chemosensitivity.
- 11 September 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (10) , 1533-1554
MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy
Limited efficacy of neoadjuvant chemotherapy (NAC) in pancreatic ductal adenocarcinoma (PDAC) underscores the need for novel combination strategies and a deeper understanding of metabolic determinants of chemoresistance. Here we identify methylmalonate semialdehyde dehydrogenase (MMSDH), a valine catabolism enzyme, as a driver of gemcitabine (GC) resistance. Hypoxia induces GCN5-mediated lactylation of MMSDH at K113. Lactylated MMSDH interacts with acyl-CoA synthetase long-chain family member 4 (ACSL4), generating propionyl-CoA to facilitate KAT8-mediated ACSL4 K606 propionylation. This modification enhances ACSL4–HSC70 binding, promoting its degradation through chaperone-mediated autophagy. Critically, this MMSDH-mediated ACSL4 propionylation correlates with low ACSL4 levels and poor NAC response in recipients. Combining dietary valine restriction with GC synergistically induces ferroptosis and suppresses tumor growth. Blocking MMSDH-K113la disrupts this axis, potentiating GC-induced ferroptosis and inhibiting tumor progression. These findings reveal a previously unknown mechanism of ferroptosis evasion through valine metabolism and ACSL4 regulation, nominating the GCN5–MMSDH–ACSL4 axis as a therapeutic target to enhance PDAC chemosensitivity.
- Open Access
- 15 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
INSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis
Aerobic glycolysis supports tumor growth, but how tumor cells sense glucose to coordinate biosynthesis remains largely unclear. Here we show that in hepatocellular carcinoma cells, glucose-activated PKCε phosphorylates the purine synthesis enzyme ADSL, triggering its translocation to the endoplasmic reticulum. ADSL then promotes succination of INSIG1/2, which disrupts the interaction between INSIG proteins and SCAP, leading to the translocation of the SCAP-SREBP complex to the Golgi, the activation of SREBP-1 and the transcription of downstream lipogenesis-related genes, proliferation of tumor cells, and tumorigenesis in mice. Through virtual screening, we identify Elsulfavirine, an approved HIV drug, which blocks ADSL-INSIG interaction and suppresses SREBP-1 activation induced by glucose. Combining Elsulfavirine with Lenvatinib synergistically inhibits tumor growth. Clinically, ADSL phosphorylation and INSIG succination correlate with SREBP-1 activation and poor prognosis in human HCC. In summary, these findings reveal a repurposing mechanism by which tumor cells coordinate glucose metabolism and lipogenesis via a moonlighting function of ADSL and underscore a repurposing strategy for liver cancer therapy.
- 15 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessINSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis
Aerobic glycolysis supports tumor growth, but how tumor cells sense glucose to coordinate biosynthesis remains largely unclear. Here we show that in hepatocellular carcinoma cells, glucose-activated PKCε phosphorylates the purine synthesis enzyme ADSL, triggering its translocation to the endoplasmic reticulum. ADSL then promotes succination of INSIG1/2, which disrupts the interaction between INSIG proteins and SCAP, leading to the translocation of the SCAP-SREBP complex to the Golgi, the activation of SREBP-1 and the transcription of downstream lipogenesis-related genes, proliferation of tumor cells, and tumorigenesis in mice. Through virtual screening, we identify Elsulfavirine, an approved HIV drug, which blocks ADSL-INSIG interaction and suppresses SREBP-1 activation induced by glucose. Combining Elsulfavirine with Lenvatinib synergistically inhibits tumor growth. Clinically, ADSL phosphorylation and INSIG succination correlate with SREBP-1 activation and poor prognosis in human HCC. In summary, these findings reveal a repurposing mechanism by which tumor cells coordinate glucose metabolism and lipogenesis via a moonlighting function of ADSL and underscore a repurposing strategy for liver cancer therapy.
- 24 October 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (10) , 935-948
Circadian genes CLOCK and BMAL1 in cancer: mechanistic insights and therapeutic strategies
The circadian clock is a highly conserved timekeeping system in organisms, which maintains physiological homeostasis by precisely regulating periodic fluct
- 24 October 2025
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 26 (10) , 935-948
Circadian genes CLOCK and BMAL1 in cancer: mechanistic insights and therapeutic strategies
The circadian clock is a highly conserved timekeeping system in organisms, which maintains physiological homeostasis by precisely regulating periodic fluct
- 27 March 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (7) , 1616-1617
ADSL-produced fumarate increases BECN1 dimethylation to promote autophagy and liver tumor growth
Cancer cells depend on the reprogramming of cell metabolism to constantly adapt metabolically to the tumor microenvironment. ADSL (adenylosuccinate lyase), a rate-limiting enzyme in de novo purine synthesis, is overexpressed in various cancer cells. However, whether ADSL functions in other oncogenic signaling is largely unknown. Here, our recent study shows that ADSL interacts with BECN1 (beclin 1) to regulate macroautophagy/autophagy upon lipid deprivation. Mechanistically, ADSL is phosphorylated at S140 by EIF2AK3/PERK (eukaryotic translation initiation factor 2 alpha kinase 3) in response to lipid deprivation, which enhances the association between ADSL and BECN1. ADSL-produced fumarate reduces the BECN1-associated KDM8 activity, leading to increased BECN1 K117 dimethylation. BECN1 K117 dimethylation inhibits its interaction with BCL2 to initiate autophagy. Targeting the ADSL-BECN1 axis by knock-in mutation or a cell-penetrating peptide inhibits autophagy and blunts liver tumor growth in mice. These findings broaden the physiological significance of ADSL in autophagy and liver tumor development.
- 27 March 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (7) , 1616-1617
ADSL-produced fumarate increases BECN1 dimethylation to promote autophagy and liver tumor growth
Cancer cells depend on the reprogramming of cell metabolism to constantly adapt metabolically to the tumor microenvironment. ADSL (adenylosuccinate lyase), a rate-limiting enzyme in de novo purine synthesis, is overexpressed in various cancer cells. However, whether ADSL functions in other oncogenic signaling is largely unknown. Here, our recent study shows that ADSL interacts with BECN1 (beclin 1) to regulate macroautophagy/autophagy upon lipid deprivation. Mechanistically, ADSL is phosphorylated at S140 by EIF2AK3/PERK (eukaryotic translation initiation factor 2 alpha kinase 3) in response to lipid deprivation, which enhances the association between ADSL and BECN1. ADSL-produced fumarate reduces the BECN1-associated KDM8 activity, leading to increased BECN1 K117 dimethylation. BECN1 K117 dimethylation inhibits its interaction with BCL2 to initiate autophagy. Targeting the ADSL-BECN1 axis by knock-in mutation or a cell-penetrating peptide inhibits autophagy and blunts liver tumor growth in mice. These findings broaden the physiological significance of ADSL in autophagy and liver tumor development.
- 6 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (5)
PCK1 inhibits cGAS-STING activation by consumption of GTP to promote tumor immune evasion
Hypoxia induces immunosuppressive phenotypes in tumor cells even in the presence of cytosolic DNA accumulation. The mechanisms by which tumor cells suppress hypoxia-induced cGAS-STING activation for immune evasion remain largely unclear. Here, we demonstrate that hypoxic stimulation induces JNK1/2-mediated S151 phosphorylation of phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis. This phosphorylation triggers the interaction between PCK1 and cGAS. The PCK1 associated with cGAS competitively consumes GTP, a substrate shared by both PCK1 and cGAS. Consequently, PCK1 inhibits GTP-dependent cGAS activation and subsequent STING-promoted immune cell infiltration and activation in the tumor microenvironment, leading to promoted tumor growth in mice. The blockade of PCK1 function, in combination with anti–PD-1 antibody treatment, exhibits an additive therapeutic effect on tumor growth. Additionally, PCK1 S151 phosphorylation is inversely correlated with cGAS-STING activation in human breast cancer specimens and patient survival. These findings reveal a novel regulation of cGAS-STING pathway and uncover the metabolic control of immune response in tumor cells.
- 6 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (5)
PCK1 inhibits cGAS-STING activation by consumption of GTP to promote tumor immune evasion
Hypoxia induces immunosuppressive phenotypes in tumor cells even in the presence of cytosolic DNA accumulation. The mechanisms by which tumor cells suppress hypoxia-induced cGAS-STING activation for immune evasion remain largely unclear. Here, we demonstrate that hypoxic stimulation induces JNK1/2-mediated S151 phosphorylation of phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis. This phosphorylation triggers the interaction between PCK1 and cGAS. The PCK1 associated with cGAS competitively consumes GTP, a substrate shared by both PCK1 and cGAS. Consequently, PCK1 inhibits GTP-dependent cGAS activation and subsequent STING-promoted immune cell infiltration and activation in the tumor microenvironment, leading to promoted tumor growth in mice. The blockade of PCK1 function, in combination with anti–PD-1 antibody treatment, exhibits an additive therapeutic effect on tumor growth. Additionally, PCK1 S151 phosphorylation is inversely correlated with cGAS-STING activation in human breast cancer specimens and patient survival. These findings reveal a novel regulation of cGAS-STING pathway and uncover the metabolic control of immune response in tumor cells.
- 29 January 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (6) , 894-905
ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation
As an enzyme with a critical role in de novo purine synthesis, adenylosuccinate lyase (ADSL) expression is upregulated in various malignancies. However, whether ADSL possesses noncanonical functions that contribute to cancer progression remains poorly understood. Here, we demonstrate that protein kinase R-like endoplasmic reticulum kinase (PERK) activated by lipid deprivation or ER stress phosphorylates ADSL at S140, leading to an enhanced association between ADSL and Beclin1. Beclin1-associated ADSL produces fumarate, which in turn inhibits lysine demethylase 8-mediated Beclin1 demethylation, resulting in enhanced Beclin1 K117me2, subsequent disruption of the binding of BCL-2 to Beclin1 and elevated autophagy. Blocking the ADSL–Beclin1 axis by knock-in mutation or a cell-penetrating peptide inhibits autophagy induced by lipid deprivation and ER stress and blunts liver tumor growth in mice. Additionally, ADSL pS140-upregulated Beclin1 K117me2 levels are positively correlated with autophagy levels in human hepatocellular carcinoma specimens and poor patient prognosis. These findings uncover the function of ADSL in autophagy regulation and liver tumor development.
- 29 January 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (6) , 894-905
ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation
As an enzyme with a critical role in de novo purine synthesis, adenylosuccinate lyase (ADSL) expression is upregulated in various malignancies. However, whether ADSL possesses noncanonical functions that contribute to cancer progression remains poorly understood. Here, we demonstrate that protein kinase R-like endoplasmic reticulum kinase (PERK) activated by lipid deprivation or ER stress phosphorylates ADSL at S140, leading to an enhanced association between ADSL and Beclin1. Beclin1-associated ADSL produces fumarate, which in turn inhibits lysine demethylase 8-mediated Beclin1 demethylation, resulting in enhanced Beclin1 K117me2, subsequent disruption of the binding of BCL-2 to Beclin1 and elevated autophagy. Blocking the ADSL–Beclin1 axis by knock-in mutation or a cell-penetrating peptide inhibits autophagy induced by lipid deprivation and ER stress and blunts liver tumor growth in mice. Additionally, ADSL pS140-upregulated Beclin1 K117me2 levels are positively correlated with autophagy levels in human hepatocellular carcinoma specimens and poor patient prognosis. These findings uncover the function of ADSL in autophagy regulation and liver tumor development.
- 17 January 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (5) , 853-863
ERK–USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth
Thymidine kinase 1 (TK1), a crucial enzyme in DNA synthesis, is highly expressed in various cancers. However, the mechanisms underlying its elevated expression and the implications for tumor metabolism remain unclear. Here we demonstrate that activation of growth factor receptors enhances TK1 expression. Treatment with epidermal growth factor or insulin-like growth factor 1 induces the binding of ERK1/2 to TK1 and subsequent TK1 S13/231 phosphorylation by ERK1/2. This modification recruits ubiquitin carboxyl-terminal hydrolase 9X to deubiquitylate TK1, preventing its proteasomal degradation. Stabilized TK1 not only enhances its enzyme activity-dependent deoxythymidine monophosphate production for DNA synthesis but also promotes glycolysis independently of its enzymatic activity by upregulating phosphofructokinase/fructose bisphosphatase type 3 expression. This dual role of TK1 drives the proliferation of human hepatocellular carcinoma cells and liver tumor growth in mice. Our findings reveal a crucial mechanism by which growth factors promote tumor development through TK1-mediated DNA synthesis and glycolysis and highlight TK1 as a potential molecular target for cancer treatment.
- 17 January 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (5) , 853-863
ERK–USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth
Thymidine kinase 1 (TK1), a crucial enzyme in DNA synthesis, is highly expressed in various cancers. However, the mechanisms underlying its elevated expression and the implications for tumor metabolism remain unclear. Here we demonstrate that activation of growth factor receptors enhances TK1 expression. Treatment with epidermal growth factor or insulin-like growth factor 1 induces the binding of ERK1/2 to TK1 and subsequent TK1 S13/231 phosphorylation by ERK1/2. This modification recruits ubiquitin carboxyl-terminal hydrolase 9X to deubiquitylate TK1, preventing its proteasomal degradation. Stabilized TK1 not only enhances its enzyme activity-dependent deoxythymidine monophosphate production for DNA synthesis but also promotes glycolysis independently of its enzymatic activity by upregulating phosphofructokinase/fructose bisphosphatase type 3 expression. This dual role of TK1 drives the proliferation of human hepatocellular carcinoma cells and liver tumor growth in mice. Our findings reveal a crucial mechanism by which growth factors promote tumor development through TK1-mediated DNA synthesis and glycolysis and highlight TK1 as a potential molecular target for cancer treatment.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Representative IHC staining images showing the expressions of SLAMF7 and CCL2 in HCC samples. Scale bar: 200 μm (left) and 20 μm (right). (B) The prognostic prediction performances of SLAMF7 in combination with CCL2 for OS and DFS in our Fudan LCI HCC cohort.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
(A) Top: Schematic showing the administration schedule of clophosome in the indicated orthotopic HCC mouse models. Bottom: Gross appearance of the liver bearing Hepa1-6 tumors in the indicated treatment groups. (B) The tumor weight and tumor volume of each group at the study endpoint (5 mice per group). NS, not significant, **P<0.01, and ***P<0.001, one-way ANOVA with a post hoc LSD test.